Programmes

NEWS

Click on the highlighted text and dots or the menu to link directly to additional information about each of these topics.

Candidate Indication Mechanism of Action Programme Status Partner
      Discovery Phase Preclinical Development Clinical Phase I Clinical Phase II  
IFN-β (SNG001) Asthma Virus Defence
 
IFN-β (SNG001) COVID-19 Virus Defence
 
IFN-β (SNG001) COPD Virus Defence
 
LOXL2 inhibitors IPF, NASH, Kidney Fibrosis & Cardiac Fibrosis Anti-fibrotic
Pharmaxis

Investors